Molecule Information

General Information of the Molecule (ID: Mol02068)

• Name: Fusion glycoprotein F0 (F) ,Respiratory syncytial virus
• Synonyms: F
• Molecule Type: Protein
• Gene Name: F
• Sequence:
  MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIE
  LSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPPTNNRARRELPRFMNYTLN
  NAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVS
  LSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVN
  AGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYV
  VQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKV
  QSNRVFCDTMNSLTLPSEINLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKT
  KCTASNKNRGIIKTFSNGCDYVSNKGMDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDP
  LVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLS
  LIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN
• Function: [Fusion glycoprotein F0]: Inactive precursor that is cleaved at two sites by a furin-like protease to give rise to the mature F1 and F2 fusion glycoproteins.
• Uniprot ID: FUS_HRSVA

Kingdom: Orthornavirae
Phylum: Negarnaviricota
Class: Monjiviricetes
Order: Mononegavirales
Family: Pneumoviridae
Genus: .
Species: .

Type(s) of Resistant Mechanism of This Molecule

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Palivizumab

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.N262D
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.N268I
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.K272E
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.K272M
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.K272Q
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.S275F
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.S275L
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.K272N
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.K272T
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.K272M
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

Disease Class: Respiratory trac infection [1]

• Resistant Disease: Respiratory trac infection [ICD-11: CA45.0]
• Resistant Drug: Palivizumab
• Molecule Alteration: Missense mutation; p.K272Q
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Schistosoma haematobium strain; 6185
• Mechanism Description: Clinical isolates N262D, K272E/M/Q, and S275F/L were reported as possessing mutations in the F protein region palivizumab-binding site (amino acids 258-275) and exhibiting resistance to palivizumab neutralization, while laboratory induced isolates N268I, and K272N/T/M/Q have also been reported.

References

• Ref 1: Neutralizing epitopes of RSV and palivizumab resistance in Japan .Fukushima J Med Sci. 2017 Dec 19;63(3):127-134. doi: 10.5387/fms.2017-09. Epub 2017 Sep 1. 10.5387/fms.2017-09